Evidence map›Paper›PMID 38842593›Full record

Observational studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2024

AI-driven discovery of blood xenobiotic biomarkers in neovascular age-related macular degeneration using iterative random forests.

Steffen E Künzel, Dominik P Frentzel, Leonie T M Flesch, Vitus A Knecht, Anne Rübsam, Felix Dreher, Moritz Schütte, Alexandre Dubrac, Bodo Lange, Marie-Laure Yaspo and 3 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Artificial intelligence to investigate metabolomics data for precision medicine.Metabolomics : Official journal of the Metabolomic Society · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Steffen E KünzelDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany. steffen-emil.kuenzel@charite.de.
Dominik P FrentzelDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
Leonie T M FleschDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
Vitus A KnechtDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
Anne RübsamDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
Felix DreherAlacris Theranostics, Max-Planck-Straße 3, 12489, Berlin, Germany.
Moritz SchütteAlacris Theranostics, Max-Planck-Straße 3, 12489, Berlin, Germany.
Alexandre DubracDépartement de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC, H3C 3J7, Canada.
Bodo LangeAlacris Theranostics, Max-Planck-Straße 3, 12489, Berlin, Germany.
Marie-Laure YaspoMax-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, 14195, Berlin, Germany.
Hans LehrachMax-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, 14195, Berlin, Germany.
Antonia M JoussenDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.
Oliver ZeitzDepartment of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Campus Benjamin Franklin (CBF), Hindenburgdamm 30, 12203, Berlin, Germany.

Funding

Novartis Pharma unrestricted research grant
6 · The paper itself

Abstract

purposeTo investigate the xenobiotic profiles of patients with neovascular age-related macular degeneration (nAMD) undergoing anti-vascular endothelial growth factor (anti-VEGF) intravitreal therapy (IVT) to identify biomarkers indicative of clinical phenotypes through advanced AI methodologies.

methodsIn this cross-sectional observational study, we analyzed 156 peripheral blood xenobiotic features in a cohort of 46 nAMD patients stratified by choroidal neovascularization (CNV) control under anti-VEGF IVT. We employed Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for measurement and leveraged an AI-driven iterative Random Forests (iRF) approach for robust pattern recognition and feature selection, aligning molecular profiles with clinical phenotypes.

resultsAI-augmented iRF models effectively refined the metabolite spectrum by discarding non-predictive elements. Perfluorooctanesulfonate (PFOS) and Ethyl β-glucopyranoside were identified as significant biomarkers through this process, associated with various clinically relevant phenotypes. Unlike single metabolite classes, drug metabolites were distinctly correlated with subretinal fluid presence.

conclusionsThis study underscores the enhanced capability of AI, particularly iRF, in dissecting complex metabolomic data to elucidate the xenobiotic landscape of nAMD and environmental impact on the disease. The preliminary biomarkers discovered offer promising directions for personalized treatment strategies, although further validation in broader cohorts is essential for clinical application.

Indexed as

BiomarkersTandem Mass SpectrometryWet Macular DegenerationXenobioticsAgedAged, 80 and overAngiogenesis InhibitorsArtificial IntelligenceChromatography, LiquidCross-Sectional StudiesFemaleHumansIntravitreal InjectionsMaleRandom ForestTomography, Optical CoherenceAngiogenesis InhibitorsBiomarkersVascular Endothelial Growth Factor AXenobioticsArtificial intelligenceIntravitreal anti-VEGF injectionsIterative Random ForestsMachine learningModifiable risk factorsNeovascular age-related macular degenerationPeripheral blood xenobioticsPersonalized medicineSystems biologyTreatment need

Identifiers

PMID38842593
PMCPMC11584439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.